Sanofi Licenses Biomunex Pharmaceuticals’ BiXAb Technology to Develop Bi- and Multi-Specific Antibodies

 Sanofi Licenses Biomunex Pharmaceuticals’ BiXAb Technology to Develop Bi- and Multi-Specific  Antibodies

Sanofi Licenses Biomunex Pharmaceuticals’ BiXAb Technology to Develop Bi- and Multi-Specific Antibodies

Shots:
  • Biomunex to receive upfronts and milestones from Sanofi. Sanofi to get rights to access Biomunex’s BiXAb technology for the development of bi- and multi-specific antibody therapies and will also be responsible for its research and global commercialization
  • The focus of the agreement is to utilize Biomunex’s platform to develop immunotherapies for multiple solid tumors including head-and-neck, gastric and pancreatic cancers
  • Biomunex’ Plug-and-Play BiXAb is biospecific antibody platform involved in the development of bi- and multi-specific antibodies in multiple therapeutic areas including immune-mediated inflammatory and infectious diseases

Click here to read full press release/ article | Ref: Biomunex Phatmaceuticals| Image: Mab Design

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post